NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix Inc (NASDAQ:CMRX) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.07. The biopharmaceutical company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $1.30 million. Chimerix had a negative return on equity of 38.75% and a negative net margin of 1,162.96%. View Chimerix's Earnings History.

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Chimerix.

3 brokerages have issued 12 month price targets for Chimerix's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $4.00 in the next year. This suggests a possible upside of 116.2% from the stock's current price. View Analyst Price Targets for Chimerix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Media headlines about CMRX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chimerix earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Chimerix.

Chimerix saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, an increase of 11.4% from the December 31st total of 1,050,000 shares. Based on an average trading volume of 777,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 2.6% of the company's shares are sold short. View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Ardelyx (ARDX), Sinovac Biotech (SVA), Organogenesis (ORGO), OrganiGram (OGI), Aptorum Group (APM), Assembly Biosciences (ASMB), Mallinckrodt (MNK), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHYF), Arcus Biosciences (RCUS), Beyondspring (BYSI), Rigel Pharmaceuticals (RIGL), BioSpecifics Technologies (BSTC), Catalyst Pharmaceuticals (CPRX) and ProQR Therapeutics (PRQR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Wynn Resorts (WYNN), SLS International (SLS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Walmart (WMT) and TherapeuticsMD (TXMD).

Chimerix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.14%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Institutional Ownership Trends for Chimerix.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Insider Buying and Selling for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $1.85.

Chimerix has a market capitalization of $113.55 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

The official website for Chimerix is http://www.chimerix.com/.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]